Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (261-270 of 352) with videos related to

Pageof 36
Sort By:
The New England Journal of Medicine|April 16, 2010
Infliximab, azathioprine, or combination therapy for Crohn's diseaseJean Frédéric Colombel, William J Sandborn, Walter Reinisch, et al.
United European Gastroenterology Journal|October 11, 2024
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome frameworkPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Inflammatory Bowel Diseases|December 10, 2024
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION StudyHiroshi Nakase, Silvio Danese, Walter Reinisch, et al.
Journal of Crohn'S & Colitis|January 31, 2016
Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet NeedsKrisztina B Gecse, Shaji Sebastian, Gert de Hertogh, et al.
Zeitschrift Fur Gastroenterologie|March 13, 2018
[Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases]Wolfgang Miehsler, Clemens Dejaco, Hans-Peter Gröchenig, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Gastroenterology|November 26, 2018
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative ColitisWilliam J Sandborn, Marcoli Cyrille, Mark Berner Hansen, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Pageof 36

Showing results (261-270 of 352) with videos related to

Sort By:
Pageof 36
The New England Journal of Medicine|April 16, 2010
Infliximab, azathioprine, or combination therapy for Crohn's diseaseJean Frédéric Colombel, William J Sandborn, Walter Reinisch, et al.
United European Gastroenterology Journal|October 11, 2024
Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome frameworkPaula Leão Moreira, Axel Dignass, Maria Manuela Estevinho, et al.
Inflammatory Bowel Diseases|December 10, 2024
Mediators of Filgotinib Treatment Effects in Ulcerative Colitis: Exploring Circulating Biomarkers in the Phase 2b/3 SELECTION StudyHiroshi Nakase, Silvio Danese, Walter Reinisch, et al.
Journal of Crohn'S & Colitis|January 31, 2016
Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet NeedsKrisztina B Gecse, Shaji Sebastian, Gert de Hertogh, et al.
Zeitschrift Fur Gastroenterologie|March 13, 2018
[Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases]Wolfgang Miehsler, Clemens Dejaco, Hans-Peter Gröchenig, et al.
BMC Gastroenterology|June 8, 2022
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysisLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Gastroenterology|November 26, 2018
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative ColitisWilliam J Sandborn, Marcoli Cyrille, Mark Berner Hansen, et al.
Journal of Crohn'S & Colitis|March 24, 2017
Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's DiseaseMaria Rosario, Jonathan L French, Nathanael L Dirks, et al.
Inflammatory Bowel Diseases|February 28, 2020
Association of Biomarker Cutoffs and Endoscopic Outcomes in Crohn's Disease: A Post Hoc Analysis From the CALM StudyWalter Reinisch, Remo Panaccione, Peter Bossuyt, et al.
BMC Gastroenterology|March 28, 2024
Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients with Crohn's disease and ulcerative colitis included in randomised controlled trialsLaurent Peyrin-Biroulet, Perttu Arkkila, Alessandro Armuzzi, et al.
Pageof 36